Get started
Author

Ole Michael Lemming

Observed names: Lemming O.M., O. Lemming, O. M. Lemming, O. Michael Lemming, Ole Lemming, Ole M Lemming, Ole M. Lemming
Institution: Lundbeck (Denmark)
ORCID: 0000-0002-7660-2054
Observed ORCID: 0000-0002-7660-2054
OpenAlex ID: A5075980189
Escitalopram 10???mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care
2002 · A. Wade, O. Michael Lemming, et al. · International Clinical Psychopharmacology · 231
Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder
2001 · S. A. Montgomery, S. Kasper, et al. · International Clinical Psychopharmacology · 187
PANSS‐6: a brief rating scale for the measurement of severity in schizophrenia
2015 · S. D. Østergaard, O. M. Lemming, et al. · Acta Psychiatrica Scandinavica · 143
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
2013 · Alireza Atri, José L Molinuevo, et al. · Alzheimer s Research & Therapy · 126
PDF
A Randomized, Double-blind, Placebo-controlled Study of Citalopram in Adolescents With Major Depressive Disorder
2006 · Anne-Liis von Knorring, Gunilla Ingrid Olsson, et al. · Journal of Clinical Psychopharmacology · 113
Escitalopram Prevents Relapse in Older Patients With Major Depressive Disorder
2007 · Philip Gorwood, Emmanuelle Weiller, et al. · American Journal of Geriatric Psychiatry · 87
Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice
1996 · M. Patris, J-M. Bouchard, et al. · International Clinical Psychopharmacology · 85
Escitalopram prevents relapse of obsessive-compulsive disorder
2007 · Naomi A. Fineberg, Brigitte Tonnoir, et al. · European Neuropsychopharmacology · 83
A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease
2013 · Nathan Herrmann, Serge Gauthier, et al. · International Psychogeriatrics · 58
The Validity of the Different Versions of the Hamilton Depression Scale in Separating Remission Rates of Placebo and Antidepressants in Clinical Trials of Major Depression
2016 · Phillip Raphael Kyle, Ole Michael Lemming, et al. · Journal of Clinical Psychopharmacology · 50
Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial
2012 · David Wilkinson, for the Study 10112 investigators, et al. · Journal of Alzheimer s Disease · 45
PDF
Citalopram and Fluoxetine in Major Depression
1997 · Thierry Bougerol, Jean-Claude Scotto, et al. · Clinical Drug Investigation · 30
Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials
2017 · Trisha Suppes, Jonas Eberhard, et al. · International Journal of Bipolar Disorders · 29
PDF
Positive and Negative Syndrome Scale-6
2016 · S. D. Østergaard, O. M. Lemming, et al. · PsycTESTS Dataset · 25
Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients
2006 · Siegfried Kasper, Ole Michael Lemming, et al. · Neuropsychobiology · 24
A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
2017 · Robert L. Findling, Adelaide S. Robb, et al. · Journal of Child and Adolescent Psychopharmacology · 21
PDF
Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
2017 · Robert L. Findling, Adelaide S. Robb, et al. · Journal of Child and Adolescent Psychopharmacology · 20
PDF
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
2022 · Andreas Meyer-Lindenberg, Jacob Nielsen, et al. · European Neuropsychopharmacology · 16
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension
2022 · John M. Kane, Bruce J. Kinon, et al. · Schizophrenia Research · 12
Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies
2021 · Jonathan Chick, Frank Andersohn, et al. · Alcohol and Alcoholism · 9
PDF
Measuring Therapeutic Efficacy in Patients with Alzheimer’s Disease: Role of Instruments
2011 · Matthias W. Riepe, Wolfgang Janetzky, et al. · Dementia and Geriatric Cognitive Disorders · 9
Sertindole in the long-term treatment of schizophrenia
2012 · Anthony S. Hale, Jean M. Azorin, et al. · International Clinical Psychopharmacology · 8
P3‐415: Effects of memantine in patients with moderate alzheimer's disease receiving stable doses of donepezil
2012 · Jose Luis Molinuevo, Ole Lemming · Alzheimer s & Dementia · 5
Adjuvant Bestatin (Ubenimex) Treatment Following Full-Dose Local Irradiation for Bladder Carcinoma
1990 · H. Blomgren, P.-L. Esposti, et al. · Acta Oncologica · 4
PDF
4.62 a Six-month Open-label Extension Study of Vortioxetine in Pediatric Patients
2016 · Robert L. Findling, Adelaide S. Robb, et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 1
Works count: 35
Citation count: 1,423
H-index: 17
I10-index: 19
Year
Topic
Type